DE69014543D1 - Multivalentes immunogen lmi. - Google Patents

Multivalentes immunogen lmi.

Info

Publication number
DE69014543D1
DE69014543D1 DE69014543T DE69014543T DE69014543D1 DE 69014543 D1 DE69014543 D1 DE 69014543D1 DE 69014543 T DE69014543 T DE 69014543T DE 69014543 T DE69014543 T DE 69014543T DE 69014543 D1 DE69014543 D1 DE 69014543D1
Authority
DE
Germany
Prior art keywords
lmi
multivalent immunogen
immunogen
multivalent
immunogen lmi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69014543T
Other languages
English (en)
Other versions
DE69014543T2 (de
Inventor
Matthew Mescher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Biology Institute
Original Assignee
Medical Biology Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Biology Institute filed Critical Medical Biology Institute
Publication of DE69014543D1 publication Critical patent/DE69014543D1/de
Application granted granted Critical
Publication of DE69014543T2 publication Critical patent/DE69014543T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69014543T 1989-03-23 1990-03-19 Multivalentes immunogen lmi. Expired - Fee Related DE69014543T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/327,822 US5045320A (en) 1989-03-23 1989-03-23 Large multivalent immunogen
PCT/US1990/001474 WO1990011085A1 (en) 1989-03-23 1990-03-19 Large multivalent immunogen

Publications (2)

Publication Number Publication Date
DE69014543D1 true DE69014543D1 (de) 1995-01-12
DE69014543T2 DE69014543T2 (de) 1995-06-22

Family

ID=23278220

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69014543T Expired - Fee Related DE69014543T2 (de) 1989-03-23 1990-03-19 Multivalentes immunogen lmi.

Country Status (5)

Country Link
US (1) US5045320A (de)
EP (1) EP0422164B1 (de)
JP (1) JP3059482B2 (de)
DE (1) DE69014543T2 (de)
WO (1) WO1990011085A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420172B1 (en) 1992-04-20 2002-07-16 Tib Company, Llc Method for inducing tumor immunity
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
US5928647A (en) * 1993-01-11 1999-07-27 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
NZ290089A (en) * 1994-07-27 1999-05-28 Queensland Inst Med Res Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines
US6033674A (en) * 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US5951975A (en) * 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
ATE283069T1 (de) 1996-08-16 2004-12-15 Univ Johns Hopkins Med Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung
US20020151690A1 (en) * 1997-08-12 2002-10-17 Luxemburg Alain T Purification of antigen-specific t cells
DE69737028T2 (de) * 1996-09-06 2007-06-28 Ortho-Mcneil Pharmaceutical, Inc. Reinigung von antigenspezifischen t-zellen
US6087174A (en) * 1996-12-26 2000-07-11 Johns Hopkins University, School Of Medicine Growth medium for primary pancreatic tumor cell culture
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
ATE407695T1 (de) 1999-02-09 2008-09-15 Riken Tumorimpfstoff
JP4688254B2 (ja) * 1999-02-09 2011-05-25 独立行政法人理化学研究所 腫瘍ワクチン

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells

Also Published As

Publication number Publication date
WO1990011085A1 (en) 1990-10-04
JPH04501853A (ja) 1992-04-02
JP3059482B2 (ja) 2000-07-04
EP0422164A1 (de) 1991-04-17
US5045320A (en) 1991-09-03
EP0422164B1 (de) 1994-11-30
DE69014543T2 (de) 1995-06-22

Similar Documents

Publication Publication Date Title
DE59000343D1 (de) Schaelmesser.
DE69020982D1 (de) Vulkanisierungsform.
DE69017059D1 (de) Mehrplattenspieler.
DE59007379D1 (de) 3-Phenylbenzofuran-2-one.
DE69005882D1 (de) Entfärbungsmittel.
DE69014543D1 (de) Multivalentes immunogen lmi.
FI891899A0 (fi) Ny biotest.
FI903226A0 (fi) Ytbelagd optisk fiber.
NO900493L (no) Dobbeltdoer-anordning.
FI906291A0 (fi) Foerbaettrad koppar-nickel-silikon-krom -legering.
DE59004522D1 (de) Mikrodosiergerät.
DE69020950D1 (de) Mehrplattenspieler.
DE59005135D1 (de) Formstein.
FI896146A (fi) Bettskivenhet.
DE69004689D1 (de) N-fluoropyridinium-pyridin-heptafluorodiborat.
DE69019836D1 (de) Verbinder.
DE59008846D1 (de) Fluorphenylpyrimidine.
DE69013427D1 (de) Glyoxyl-Cyclohexendione.
FI890299A (fi) Form.
DE59007719D1 (de) Pyrazol-3-carbonsäureamide.
DE68916800D1 (de) Verbinder.
DE69008037D1 (de) Satteldecke.
DE59004256D1 (de) Augentropfen.
FI903560A0 (fi) Lim foer golvbelaeggningar.
FI890300A (fi) Form.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee